These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 32145207)
21. Accelerated approval of drugs: ethics versus efficacy. Chary KV; Pandian K Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403 [TBL] [Abstract][Full Text] [Related]
22. The US Biosimilar Market: Stunted Growth and Possible Reforms. Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479 [TBL] [Abstract][Full Text] [Related]
23. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. Moore TJ; Furberg CD JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236 [TBL] [Abstract][Full Text] [Related]
24. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study. Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641 [TBL] [Abstract][Full Text] [Related]
25. More New Medication Approvals. Turkoski BB Orthop Nurs; 2016; 35(4):255-8. PubMed ID: 27441881 [TBL] [Abstract][Full Text] [Related]
26. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation. Kwok M; Foster T; Steinberg M Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571 [TBL] [Abstract][Full Text] [Related]
27. On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics. Gopal AD; Wallach JD; Shah SA; Regillo C; Ross JS Ophthalmology; 2021 Feb; 128(2):332-334. PubMed ID: 32682839 [No Abstract] [Full Text] [Related]
28. Pharmaceuticals and Medical Devices: FDA Oversight. White RS; Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-43. PubMed ID: 29361661 [No Abstract] [Full Text] [Related]
29. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018. Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430 [TBL] [Abstract][Full Text] [Related]
30. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. Yeh JS; Sarpatwari A; Kesselheim AS Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800 [TBL] [Abstract][Full Text] [Related]
31. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. Chen EY; Raghunathan V; Prasad V JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822 [TBL] [Abstract][Full Text] [Related]
32. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations. Daizadeh I Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936 [TBL] [Abstract][Full Text] [Related]
33. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014. Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974 [TBL] [Abstract][Full Text] [Related]
34. 2021 in review: FDA approvals of new medicines. Kinch MS; Kraft Z; Schwartz T Drug Discov Today; 2022 Aug; 27(8):2057-2064. PubMed ID: 35439613 [TBL] [Abstract][Full Text] [Related]
35. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457 [TBL] [Abstract][Full Text] [Related]
36. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. Mostaghim SR; Gagne JJ; Kesselheim AS BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831 [No Abstract] [Full Text] [Related]
37. Parental preferences for FDA-approved medications prescribed for their children. Yoon EY; Clark SJ; Butchart A; Singer D; Davis MM Clin Pediatr (Phila); 2011 Mar; 50(3):208-14. PubMed ID: 21098519 [TBL] [Abstract][Full Text] [Related]
38. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer. Yamashita K; Kaneko M; Narukawa M Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731 [TBL] [Abstract][Full Text] [Related]
39. Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs. Kesselheim AS; Tan YT; Darrow JJ; Avorn J Health Aff (Millwood); 2014 Oct; 33(10):1770-8. PubMed ID: 25288421 [TBL] [Abstract][Full Text] [Related]
40. Controversy still swirls around FDA user fees: since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals--but does speed equal safety? Ullman K Ann Neurol; 2013 Nov; 74(5):A10-1. PubMed ID: 24353218 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]